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Received March 5, 2012; accepted August 9, 2012AbstractBackground: Aortic valve replacement (AVR) remains the gold standard treatment for symptomatic severe aortic stenosis (AS). For the past
10 years, transcatheter aortic valve implantation (TAVI) has been applied in patients with high surgical mortality and morbidity risks. The
preliminary results of our TAVI patients are presented in this study.
Methods: Ten high-risk patients with severe AS, for AVR, were referred and accepted for TAVI in the 6 month period from May 2010 to October
2010. The patient age, logistic EuroSCORE, femoral arterial diameter, aorta annulus size, aorta valve area (AVA), mean aortic pressure gradient
(MPG), as well as coronary angiography results were all collected. Six patients were treated via the transapical approach in March 2010, whereas
the other four were treated with the transfemoral approach, according to their femoral artery diameter and arterial quality. This study focuses on
the immediate, 1 month, 3 month, and 1 year results of TAVI.
Results: The average age of the 10 patients receiving TAVI was 81.5 years. The mean calculated EuroSCORE was 28.3  7.9%. The mean AVA
was 0.61  0.19 cm2. The MPG was 48  16 mmHg. The surgical technical success achieved 100%. There was no reported moderate to severe
postoperative paravalvular aortic regurgitation, permanent complete atrioventricular block, major access site complication, or embolic stroke.
Chronic renal failure, which necessitated permanent hemodialysis, developed in 10% of the patients. One acute myocardial infarction and one
case of pneumonia developed postoperatively. The AVAwas increased by 251%, whereas the MPG was decreased by 80% at the 3 month follow-
up. The 30-day mortality rate was 10%. The all-cause 1-year mortality rate was 20%.
Conclusion: This new technique and device requires greater caution and needs more practice to accumulate sufficient experience. The studied
patients were very fragile, due to old age and multiple comorbidities. Our results are similar to findings of multicenter trials. With careful patient
screening and selection, TAVI can be a promising treatment for high-risk severe AS patients.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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With improvement of the public health environment,
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http://dx.doi.org/10.1016/j.jcma.2013.08.007world. However, valvular heart diseases have not shown any
trend of decreasing, whereas the number of degenerative
valvular diseases is increasing. Among the population aged 75
years and over, 12.5% have degenerative valvular disease and
33.9% have valvular aortic stenosis.1,2 Surgical aortic valve
replacement (SAVR) remains the gold standard treatment for
symptomatic severe aortic stenosis (AS). With appropriate
patient selection, SAVR was reported to be associated with a
low operative mortality rate.3e5 However, at least 30% ofhinese Medical Association. All rights reserved.
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multiple comorbidities, old age, and poor pulmonary or heart
function.6,7 For octogenarians and nonagenarians, SAVR 1-
year mortality rate was 13% with high morbidity and pro-
longed intensive care and hospitalization. The risk can be as
high as 25% with comorbid conditions.8e10 Hence, there
should be some less invasive alternatives for those who are at
risk. Transcatheter aortic valve implantation (TAVI) has been
developed in the past decade.8,11,12 According to the currently
published results of the Placement of Aortic Transcatheter
Valve trial (PARTNER-II), the outcomes between conservative
treatment (including medication and percutaneous trans-
luminal balloon aortic valvuloplasty) and TAVI were
compared; all had severe AS and were not candidates for
SAVR. According to the PARTNER II results, the 1-year
mortality rates for conservative treatment and TAVI were
49.7% and 30.7%, respectively.12 In this study, we pioneer the
use of the TAVI procedure for treatments in severe symp-
tomatic AS in Taiwan. The acute and short-term results have
been delivered in our previously published article.13 The mid-
term efficacy and safety were further evaluated with 1-year
follow-up, and the acute and mid-term results were also
compared to evaluate the applicability and durability of this
device.
2. Methods2.1. Patient selectionBetween May 2010 and October 2010, 10 patients received
TAVI at our hospital. This trial was approved by the Ethics
Committee of Taipei Veterans General Hospital. Informed
consent was obtained from all patients. All potential candi-
dates for TAVI were evaluated by a multidisciplinary team that
was composed of interventional cardiologists and cardiac
surgeons. Patients who were considered to be eligible for TAVI
underwent a systematic workup protocol that included
Doppler echocardiography, coronary angiography, aortoilio-
femoral angiography, and computed tomography. Depending
on the size, disease, and degree of calcification of iliofemoral
arteries, the patients were selected for treatment by either the
transfemoral (TF) approach or the transapical approach (TA).
The TF approach was the treatment of choice. The Edwards
Sapien valve (Edwards LifeSciences, Irvine, Calif) was used in
all cases. The 23 mm valve was implanted if the trans-
esophageal echocardiographic (TEE) measurement of the
aortic annulus was between 18 mm and 21 mm, and the
26 mm valve was implanted if the aortic annulus measured
between 22 mm and 25 mm. Patients’ comorbidities and the
related surgical risks were defined with logistic EuroSCORE.
The inclusion and exclusion criteria were described as follows.2.2. Inclusion criteriaPatients who met the following criteria were included: se-
vere and symptomatic AS with aortic valve area (AVA)
<1 cm2, mean pressure gradient >40 mmHg, NYHAfunctional class was above class II, the aortic valve annulus
diameter was between 18 mm and 25 mm on echocardiogra-
phy, the distance between the coronary sinus and annulus was
>1 cm, the patients were 80 years old, and the patients had a
high surgical risk with a logistic EuroSCORE >20%. Each
patient was declined by at least two surgeons for surgical
aortic valve replacement.2.3. Exclusion criteriaPatients with bicuspid or non-calcified aortic valve are not
suitable for TAVI. Those with an intracardiac tumor, thrombus,
or other conditions that require open heart surgery other than
aortic stenosis, e.g., untreated coronary arterial disease
requiring surgical revascularization, are also excluded. The
left ventricular ejection fraction (LVEF) cannot be <20%. The
annulus diameter (echo data) should be between 18 mm and
25 mm. The patient should be under a relatively stable con-
dition. Therefore, those with the following conditions were
also excluded: acute myocardial infarction within 1 month,
acute pulmonary embolism, stoke, or transient ischemic attack
(TIA) within 1 month, life expectancy <12 months, or little
hope for a meaningful lifestyle. The access route should also
be considered; patients with iliofemoral disease, insufficient
femoral artery diameter, or aortic dissection were all excluded
from the TF approach.2.4. TAVI procedureThe TAVI procedure was completed in a standard cardiac
catheterization room. Under general anesthesia and a sterile
environment, the patient was under full monitor, including a
cerebral oximeter and transesophageal echocardiography. For
the patients who received the TF approach, bilateral femoral
arteries were cut down. The brain protection embolic filter
(Filter Wire EZ Embolic Protection System, Boston Scientific,
USA) was placed via one side of the femoral artery. Then, the
standard balloon valvular dilatation was performed. The valve
stent was then launched via the other side of the femoral artery.
After confirming the annulus site under C-arm fluorometry, the
Sapien valve stent was deployed with rapid ventricular pacing.
Balloon dilatation was performed again to fit the valve.
As for the TA approach, the embolic protection filter was
also placed first via the femoral artery. Then a mini-
thoracotomy was performed. The apex was identified, and
the standard “box suture” was applied. A guide wire and a
sheath were inserted. Balloon valvuloplasty was performed
first. Then the Edwards Sapien valve stent was deployed via
the sheath over the apex, under rapid ventricular pacing and C-
arm fluorometry.2.5. Outcome evaluationThe efficacy and safety of the TAVI procedure was evalu-
ated immediately postoperative, at 30 days, and at 1 year.
Clinical and echocardiographic data were obtained prior to
discharge and then monthly.
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Patients’ demographic data and early procedural outcomes
(first 24 hours) were mentioned in our previous article in Acta
Cardiologica Sinica13. Among the 10 patients enrolled, the
average age was 81.5 years. The mean logistic EuroSCORE
was 28.3  7.9. None of the patients had received surgical
coronary revascularization, whereas one patient had received
surgical mitral valve replacement > 10 years ago. There was
no patient with conduction disturbance or a pacemaker pre-
operatively. The mean LVEF was 61  9%. The mean aortic
pressure gradient was 48  16 mmHg. The mean AVA was
0.61  0.19. The procedural success rate reached 100%. There
was no periprocedural death, valve embolization, malposition,
stroke, or coronary artery obstruction. One acute myocardial
infarction developed in the TA group within the first 24 hours,
which resulted in right ventricle rupture on postoperative Day
3. No additional endovascular intervention was performed.
There was no reported severe aortic regurgitation (>Grade II/
IV), major access site and all-cause vascular complication,
acute renal failure, new onset aortic regurgitation, or atrial
fibrillation. Six transient left bundle branch block (LBBB)
developed right after TAVI but resolved within 1 week.3.1. Short-term outcomes (2e30 days)No major access site complication developed during this
period (Table 1). One patient with chronic renal failure
developed acute renal failure, which required long-term he-
modialysis. One patient (10%) developed pneumonia and
ended up with septic shock on postoperative Day 29. It was the
only mortality case within the period. No cerebral vascular
events were reported. One patient developed right ventricle
(RV) rupture in the TA group. It was suspected that post-
operative acute myocardial infarction (AMI) on postoperative
Day 3 was the cause. Cardiac tamponade then developed and
the patient was sent to the operation room for immediate
surgery. The patient recovered without any significant events
after RV repair and was discharged on postoperative Day 21.3.2. Echocardiographic findingsThe acute echocardiographic findings are as follows13: at
discharge, the mean AVA was 1.42 cm2, mean aortic pressureTable 1
Short-term outcomes (2e30 days).
Variables Transapical
n ¼ 6
Transfemoral
n ¼ 4
Both procedures
n ¼ 10
Bleeding 16.7 0 10
Major access site complication 0 0 0
Myocardial infarction 0 0 0
Stroke 0 0 0
Need for hemodialysis 16.7 0 10
Need for permanent pacemaker 0 0 0
Pneumonia 16.7 0 10
30-day mortality 16.7 0 10
Data are presented as %.gradient (MPG) was 11 mmHg, and mean PPG was 18 mmHg
(Figs. 1 and 2). At 1-year follow-up, they became 1.2 cm2,
13.2 mmHg, and 10.6 mmHg, respectively. The MPG
decreased to 23%, and the PPG decreased to 20% at the 3-
month follow-up, but then mildly increased to 28% and 23%
at 1-year follow up ( p ¼ 0.104), respectively. The AVA
increased to 251% from the baseline at the 3-month follow-up
but mildly decreased to 197% at 1-year follow-up ( p ¼ 0.002).
Thirty percent of the patients had moderate to severe AR
preoperatively. At discharge, 50% of the patients were free
from paravalvular AR. At 3-month follow-up, 70% of the
patients had trivial or no AR, and the results remained the
same throughout the rest of the year. No patient had AR >2þ.3.3. Mid-term (30 daye1 year) mortality and major
morbidityThe all-cause 30-day mortality was 10%, whereas the all-
cause 1-year mortality was 20% (Table 2). There was zero
cardiovascular mortality at 30-day and 1-year follow-up. No
ischemic stroke developed during 1-month follow-up. One pa-
tient developed hemorrhagic stroke with brainstem failure,
which led to mortality on postoperative Day 173. There was no
severe paravalvular AR, conduction disturbance, and myocar-
dial infarction between the 1-month and 1-year follow-up.
4. Discussion
SAVR used to be the only effective treatment for severe
symptomatic AS. For patients with high surgical risks, balloon
aortic valvuloplasty was an alternative option for symptomatic
relief, although the long-term durability was not satisfactory
and the procedure-related mobility and mortality was too
high.10 TAVI was introduced and Cribier and colleagues began
applying it to clinical practice in 2002.14 Recently, it was
proven that TAVI has a similar 1-year mortality rate as SAVR,
but with less bleeding complications in patients who were
evaluated to be of relatively high risk for surgery.15 It was
reported that the TF approach had a better outcome than the
TA approach. Generally speaking, TA patients had higher risks
because of the selection bias associated with the delivery
approach. The patients selected for the TA approach had a
higher incidence for multiple comorbidities and worse vesselFig. 1. Mean and peak pressure gradient during 1-year follow-up. The mean
aortic pressure gradient (MPG) was 11 mmHg, and the mean PPG was
18 mmHg at discharge, 10 mmHg, and 17 mmHg, respectively, at 3-month
follow-up, and 13.5 mmHg and 20.6 mmHg, respectively, at 1-year follow up.
Fig. 2. Aortic valve area (AVA), baseline data and up to 1-year follow-up. The
mean AVA was 1.42 cm2 at discharge, 1.45 cm2 at 3-month follow-up, and
1.2 cm2 at 1-year follow-up.
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to <4% in the TF cohort. In our study group, the two mortality
cases were both treated via the TA approach. According to
other single-center studies, 32e52% of the TAVI patients
required the TA approach.11,12,17 However, in our study, 60%
of the patients received TAVI via the TA approach. Due to the
relatively small size of femoral arteries in the Asian popula-
tion, there is a higher proportion of patients who cannot
accommodate the 22/24 French catheter for the 23/26 mm
valve. Thus, reducing the catheter profile may definitely in-
crease the number of TF cases.
From previous reports, TAVI allowed treatments for up to
76% of the patients who were previously declined for
SAVR.16,17 In our study, the 30-day mortality was 10%
(pneumonia with septic shock on postoperative Day 26) and
the 1-year mortality was 20% (hemorrhagic stroke with
brainstem failure in the 6th month postoperatively). No patient
died from cardiovascular complications. In the recently pub-
lished results of the PARTNER II trial, the 30-day mortality
was 5%, whereas the 1-year mortality was 30.7%.2 The car-
diovascular 30-day and 1-year mortality in our hospital were
both 0%, whereas they were 4.5% and 19.6%, respectively, in
the PARTNER II trial. There was one major hemorrhagic
stroke in our study, which was not procedural-related.
TAVI has a high procedural success rate of 93.8%.9 Some
patients may need multiple valve implantation or conversion to
SAVR, due to immediate procedural complications, such as
valve embolization, migration, leakage, aortic dissection, orTable 2
Intermediate-term (30 dayse1 year) mortality and major morbidity.a
Variables Transapical
n ¼ 6
Transfemoral
n ¼ 4
Both procedures
n ¼ 10
Stroke 16.7 0 10
Pneumonia 0 0 0
Need for hemodialysis 16.7 0 10
Myocardial infarction 0 0 0
Major access site complication 0 0 0
Need for permanent pacemaker 0 0 0
Cardiac-caused rehospitalization 0 0 0
30 daye1 year mortality 16.7 0 20
Data are presented as %.
AR ¼ aortic regurgitation; ICH ¼ intracerebral hemorrhage; ARF ¼ acute
renal failure; PPG ¼ peak pressure gradient.
a One patient died in the 9th postoperative month due to spontaneous ICH
with brainstem failure. One patient developed ARF after 48 hours, received
dialysis with recovery but refractory ARF developed.aorta rupture.2,9,18 In our trial, the immediate procedural
success rate was 100%. No patient needed reintervention for
aortic valve replacement. However, there was one case of AMI
on postoperative Day 1, resulting in RV rupture. Emergent
reopening of the chest was done for RV repair. The patient
was discharged on postoperative Day 21 without major
morbidities.
The heart failure symptoms were greatly reduced after
TAVI. The average NYHA function class was decreased to
Class II after 1-month follow-up. The biomarker for heart
failure, NT-proBNP, was also decreased. There was a 56%
decline at the 1-month follow-up and 62% at the 1-year
follow-up. The mean increase in AVA was 251% on post-
operative Day 30, whereas it was 250% in the PARTNER trial.
Moreover, the MPG decreased 80.0% in 1-month follow-up,
whereas that of the PARTNER trial was 75.1%.2
Vascular complication was also a major consideration. The
total vascular complication rate was approximately 12%.19,20
The access-related vascular complication accounted for
72.7% of all vascular complications, especially in the TF
group. Major vascular complications may be a prognostic
factor of the 30-day mortality of the TA group. However, it
was reported that the approach site complication does not
affect the 30-day and 1-year mortality of the TF group. There
was no distal embolization, femoral artery pseudoaneurysm
formation, femoral-iliac artery dissection or rupture, or aortic
dissection or rupture. Although one patient from the TF group
was accessed by external iliac artery cut-down, due to a
relatively small femoral artery diameter, there was no vascular
complication. We believe that with careful access site evalu-
ation, patient selection for the TF approach and matured
technique, arterial complications, such as local dissection,
distal embolization, and major bleeding, can be minimized.
The improvement of the device and reduction of the catheter
profile may also be beneficial.
Atrioventricular block was another usual complication for
TAVI. About 4e7% patients needed a new pacemaker for
irreversible atrioventricular block.2,12 In our patient group,
six (60%) developed transient LBBB immediately after TAVI.
Five of them resolved within 24 M hours, and only one pa-
tient had LBBB for 6 days. There was no new-onset atrial
fibrillation, advanced atrioventricular block, or RBBB at
3 months. No patient required a permanent pacemaker
implantation.
This study showed zero incidence of new-onset moderate to
severe paravalvular AR in the patients receiving TAVI. The
results were superior to other international clinical trials. The
reported new-onset paravalvular AR rate exceeded 10e22% at
both the 30-day follow-up and the 1-year follow-up.2,21,22
Aortic regurgitation happened frequently after both SAVR
and TAVI. Most of the cases were minor leaks without he-
modynamic consequences. Severe AR (>2/4) may lead to LV
remodeling and hemolytic anemia and may lead to rein-
tervention.18,22e24 After TAVI, significant AR may be related
to prosthesis/annulus discongruence, malpositioning, or severe
calcified cusps of the native valve or bicuspid valve.25 The
exclusion of bicuspid aortic valve in our trial, detailed
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contribute to the low incidence of paravalvular AR.
Among our patients, 80% had variable degrees of pulmo-
nary diseases. The 30-day mortality was attributed to a pul-
monary complication, revealing that the lung condition might
be a main predictor for prolonged hospitalization and
morbidity. The pulmonary complication mainly resulted from
general anesthesia. The morbidity and mortality rate will
decrease largely if local anesthetic TAVI becomes applicable
with the improvement of device and modification of
technique.
The bovine bioprosthetic valve stent performed well within
the 1-year follow-up period. There was no valve dysfunction
detected during 1-year follow-up. However, it is revealed that
the increased AVA after the procedure went down slightly at 1
year ( p ¼ 0.002). The transvalvular pressure gradient decrease
after TAVI seemed to rebound at 1-year follow up, although
the data was statistically insignificant ( p ¼ 0.104). The long
term durability of the valve should be examined and followed
up by further study.
TAVI patients have the potential of being promoted to the
high-risk AS patients, who are not suitable for surgery. Our
study presented results similar to the international multi-center
trial data. However, this is a single-center clinical trial. Further
randomized trials with a longer follow-up period and a larger
sample size should be carried out for more accurate results of
the safety and efficacy of TAVI.
In conclusion, this new technique and the device require
greater caution and needs more practice to accumulate suffi-
cient experience. The studied patients were very fragile due to
old age and multiple comorbidities. Our results are similar to
findings of multi-center trials. Further studies should be car-
ried out on long-term durability and applicability.
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